Table I.
Applications of treatments in senescence-related lymphoma resistance.
| Classification | Drug name | Target | Phase | NCT number | Diseases | (Refs.) |
|---|---|---|---|---|---|---|
| Senolytics | KW-2478 AUY922 | Hsp90 inhibitor | Phase I/Phase II | NCT00457782/NCT01485536 | B cell malignancies/NHL | (116,117) |
| Bortezomib | Proteasome inhibitor | Phase III/Phase III | NCT00722137/NCT02112916 | MCL/T-LL | (124,125) | |
| Navitoclax (ABT263) | Bcl-2/Bcl-xL inhibitors | Phase I | NCT03181126 | R/R ALL or LL | (132) | |
| SSK1 | β-galactosidase | Preclinical | - | Targeting senescent cells | (143) | |
| JQ1/RVX2135 | BETi | Preclinical | - | Myc-induced lymphoma mice | (144) | |
| Alisertib | Aurora kinase A inhibitor | Phase I/II | NCT01397825/NCT00807495 | R/R aggressive B-cell and T-cell lymphoma | (121,122) | |
| Pathway inhibitors | Temsirolimus | mTOR inhibitor | Phase I/Phase II | NCT01076543 | R/R lymphoma (including DLBCL/FL/cHL) | (127) |
| Crenigacestat | NOTCH inhibitor | Phase I | NCT02518113 | R/R T-ALL/T-LBL | (128) | |
| Ruxolitinib | JAK inhibitor | Phase II/Phase II | NCT02974647/NCT02164500 | R/R PTCL/cHL | (130,131) | |
| Immunoadjuvant therapy | PD-1 inhibitor | PD-1 inhibitor | Preclinical | - | T-cell lymphomas/B-cell lymphomas | (95,99) |
| NAD+ precursor nicotinamide riboside | NAD+ precursor nicotinamide riboside | Preclinical | - | Targeting senescent T-cells | (28) |
R/R, relapsed or refractory; T-ALL, T-cell acute lymphoblastic leukemia; T-LL, T-cell lymphoblastic lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; cHL, classical Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; PTCL, peripheral T-cell lymphoma; HSP, heat shock protein; PD-1, programmed cell death 1; BETi, bromodomain and extra-terminal inhibitors; NCT, National Clinical Trials.